Drug intelligence / Profile preview

N-Heptylformamide

Development stage: Unknown
Modality: Small Molecules

Overview

N-Heptylformamide is a small molecule that functions as a potent and selective inhibitor of various alcohol dehydrogenase (ADH) isoenzymes. It has been shown to inhibit human ADH4, HsADH sigma, and HsADH beta1. This compound has been utilized in research to investigate the metabolism of 20-hydroxyeicosatetraenoic acid (20-HETE) in cerebral microvessels, where it decreased the conversion of 20-HETE to 20-carboxyeicosatetraenoic acid (20-COOH-AA) by inhibiting ADH4. Additionally, N-Heptylformamide has been employed in structural studies to understand the binding characteristics and substrate preferences of different ADH isoenzymes.

Other names: N-heptylformamideFormamide, N-heptyl-

Targets

ADH1B (Alcohol dehydrogenase beta-1 subunit)ADH7 (Alcohol dehydrogenase 7)

Beyond the preview

Go deeper on N-Heptylformamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-Heptylformamide.

Explore the full profile